MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates

Journal of Infectious Diseases

Volumn 174, Issue 6, 1996, Pages 1168-1175

  Traquina, P ^a   Morandi, M ^a   Contorni, M ^a   Van Nest, G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BABOON; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFICACY; DRUG INTERACTION; DRUG POTENTIATION; EMULSION; FEMALE; HEPATITIS B VIRUS; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NONHUMAN; PHARMACOLOGY; PRIORITY JOURNAL; VACCINATION;

EID: 0029852624     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/174.6.1168     Document Type: Article

References (17)

1. André FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989;87:14S-20S.
2. Bryan JP, Sjogren M, Iqbal M, et al. Comparative trial of low-dose, intradermal, recombinant- and plasma-derived hepatitis B vaccines. J Infect Dis 1990; 162:789-92.
3. Scolnick EM, McLean AA, West DJ, McAleer WJ, Miller WJ, Buynak EB. Clinical evaluation in healthy adults of a hepatitis B vaccine made by recombinant DNA. JAMA 1984;251:2812-5.
4. Wiedermann G, Scheiermann N, Goubau P, et al. Multicenter dose range study of a yeast-derived hepatitis B vaccine. Vaccine 1987;5:179-83.
5. Miskovsky E, Gershman K, Clements ML, et al. Comparative safety and immunogenicity of yeast recombinant hepatitis B vaccines containing S and pre-S2+S antigens. Vaccine 1991;9:346-50.
6. Coursaget P, Bringer L, Sarr G, et al. Comparative immunogenicity in children of mammalian cell-derived recombinant hepatitis B vaccine and plasma-derived hepatitis B vaccine. Vaccine 1992; 10:379-82.
7. Leroux-Roels G, Van Hecke E, Michielsen W, Voet P, Hauser P, Pêtre J. Correlation between in vivo humoral and in vitro cellular immune responses following immunization with hepatitis B surface antigen (HBsAg) vaccines. Vaccine 1994; 12:812-8.
8. Stephenne J. Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness. Vaccine 1988; 6:299-303.
9. Wainwright RB, McMahon BJ, Bulkow LR, et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA 1989; 261:2362-6.
10. Mintai Z, Kezhou L, Lieming D, Smego RA Jr. Duration and efficacy of immune response to hepatitis B vaccine in high-risk Chinese adolescents. Clin Infect Dis 1993; 16:165-7.
11. Just M, Berger R, Scheiermann N. Persistence of antibodies following vaccination with a yeast-derived recombinant hepatitis B vaccine. Vaccine 1988;6:401-2.
12. Jilg W, Schmidt N, Deinhardt F, Zachoval R. Hepatits B vaccination: how long does protection last? Lancet 1984;2:458.
13. Hauler SC. Are booster doses of hepatitis B vaccine necessary? Ann Intern Med 1988;108:457-8.
14. Wainwright RB, McMahon BJ, Bulkow LR, Parkinson AJ, Harpster AP. Protection provided by hepatitis B vaccine in a Yupik Eskimo population. Arch Intern Med 1991; 151:1634-6.
15. West DJ, Calandra GB, Hesley TM, Ioli V, Miller WJ. Control of hepatitis B through routine immunization of infants: the need for flexible schedules and new combination vaccine formulations. Vaccine 1993; 11:S21-7.
16. Esteban JI, Genesca J, Esteban R, et al. Immunoprophylaxis of perinatal transmission of the hepatitis B virus: efficacy of hepatitis B immune globulin and hepatitis B vaccine in a low-prevalence area. J Med Virol 1986;18:381-91.
17. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315:209-14.